HKEX Filings
-
Jun 18, 2024
VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES POSITIVE PRELIMINARY PHASE I RESULTS FOR BIVALENT RSV VACCINE CANDIDATE SCB-1019 IN OLDER ADULT AND ELDERLY COHORT
-
Jun 4, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended May 31, 2024
-
May 6, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended April 30, 2024
-
Apr 25, 2024
Form of Proxy for Use at Annual General Meeting
-
Apr 25, 2024
Notice of Annual General Meeting
-
Apr 25, 2024
2023 Annual Report
-
Apr 25, 2024
(1). Proposed Grant of General Mandates to Repurchase Shares and to Issue New Shares; (2). Proposed Re-Election of the Retiring Directors; (3). Proposed Re-Appointment of Auditor; (4). Proposed Amendments to the Memorandum And Articles of Association; And (5). Notice of Annual General Meeting
-
Apr 8, 2024
VOLUNTARY ANNOUNCEMENT CLOVER ANNOUNCES POSITIVE PRELIMINARY PHASE I RESULTS FOR BIVALENT RSV VACCINE CANDIDATE SCB-1019 IN INITIAL YOUNG ADULT COHORT
-
Apr 3, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended March 31, 2024
-
Apr 2, 2024
GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
-
Mar 27, 2024
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
-
Mar 14, 2024
DATE OF BOARD MEETING
-
Mar 4, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 29, 2024
-
Feb 22, 2024
Letter to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
-
Feb 22, 2024
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
-
Feb 2, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2024
-
Jan 3, 2024
Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2023
-
Dec 29, 2023
VOLUNTARY ANNOUNCEMENT - CLOVER ANNOUNCES POSITIVE PHASE I RESULTS FOR SCB-219M FOR TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)
-
Dec 28, 2023
GRANT OF EXTENSION OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14A.53 OF THE LISTING RULES UNDER THE LICENSE AGREEMENT
-
Dec 13, 2023
VOLUNTARY ANNOUNCEMENT - CLOVER INITIATES PHASE I CLINICAL TRIAL FOR RSV VACCINE CANDIDATE